The team at Atara Biotherapeutics announced EU Approval on their allogeneic T-cell therapy to treat adult and pediatric patients 2 years of age and older with relapsed or refractory Epstein-Barr virus (EBV) positive post-transplant lymphoproliferative disease (PTLD).
Modality Solutions supported Atara by developing short-term shipping solutions, a transport validation and shipper qualification strategy. We are honored to be a part of the first-ever globally approved allogeneic (donor-derived) T-cell immunotherapy.
Read the full Atara Press Release, or check out our case study on the cold chain engineering work Modality Solutions provided to support Atara’s approval.
“Modality Solutions approach to leveraging integrated technologies to orchestrate and supply commercial activities directly impacted our success.” – VP, Technical Operations, Atara
Today, four leading life science companies—Suttons Creek, Modality Solutions, CLINTREX, and ToxStrategies—announce their unification...
read Details
Modality Solutions is proud to announce the launch of our new Greenwood Lab—a state-of-the-art...
read Details
Congratulations to Vertex for their UK approval for CASGEVY™, a CRISPR/Cas9 gene-edited therapy, for...
read Details
